Differential effects of typical and atypical neuroleptics on mitochondrial functionin vitro

Archives of Pharmacal Research

Volumn 26, Issue 11, 2003, Pages 951-959

  Modica Napolitano, Josephine S ^a   Lagace, Christopher J ^b   Brennan, William A ^c   Aprille, June R ^d  

^a MERRIMACK COLLEGE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Augusta Mental Health Institute   (United States)

^d UNIVERSITY OF RICHMOND   (United States)

Author keywords

Electron transport; Extrapyramidal symptoms; Mitochondrial bioenergetic function; Neuroleptics; Oxidative phosphorylation; Respiratory enzyme complex I; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; LIVER MITOCHONDRION; MALE; METABOLISM; OXYGEN CONSUMPTION; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MITOCHONDRIA, LIVER; OXYGEN CONSUMPTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3042550340     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/BF02980205     Document Type: Article

References (30)

1. Andreassen, O. A. and Jorgensen, H. A., The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia?Psychopharmacol., 119, 474–476 (1995). DOI: 10.1007/BF02245864
2. Andreassen, O. A. and Jorgensen, H. A., Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: Implications for tardive dyskinesia.Prog. Neurobiology, 61, 525–541 (2000). DOI: 10.1016/S0301-0082(99)00064-7
3. Balijepalli, S., Boyd, M. R., and Ravindranath, V., Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation.Neuropharmacology, 38, 567–577 (1999). DOI: 10.1016/S0028-3908(98)00215-9
4. Beal, M. F. Hyman, B.T., and Koroshetz, W., Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?Trends Neurosci., 16, 125–131 (1993). DOI: 10.1016/0166-2236(93)90117-5
5. Beal, M. F., Aging, energy and oxidative stress in neurodegenerative diseases.Ann. Neurol., 38, 357–3661 (1995). DOI: 10.1002/ana.410380304
6. Beasley, C. M., Jr., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., and Beuzen, J. N., Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.Eur. Neuropsychopharmacol., 7, 125–137 (1997). DOI: 10.1016/S0924-977X(96)00392-6
7. Burkhardt, C., Kelly, J. P., Lim, Y.-H., Rilley, C. M., and Parker, W. D., Jr., Neuroleptic medications inhibit complex I of the electron transport chain.Ann. Neurol., 33, 512–517 (1993). DOI: 10.1002/ana.410330516
8. Byczkowski, J. Z. and Borysewicz, R., The action of chlorpromazine and imipramine on rat brain mitochondria.Gen. Pharmac. 10, 369–372 (1979).
9. Casey, D. E., Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models.Br. J. Psychiatry Suppl., 168(29), 32–39 (1996).
10. Chouinard, G., Ross-Chouinard, A., Annable, L, and Jones, B. D., The extrapyramidal symptom rating scale.Can. J. Neurol. Sci., 7, 233 (1980).
11. Gallagher, C. H., Koch, J. H., and Mann, D. M., The effect of phenothiazine on the metabolism of rat liver mitochondria.Biochem. Pharmacol., 10, 369–372 (1965).
12. Glazer, W. M., Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.J. Clin. Psychiatry, 61[suppl 3], 16–21 (2000).
13. Goff, D. C., Tsai, G., Beal, M. F., and Coyle, J. T., Tardive dyskinesia and substrates of energy metabolism in CSF.Am. J. Psychiatr., 152, 1730–1736 (1995).
14. Green, D. R. and Reed, J. C., Mitochondria and apoptosis [Review].Science, 281, 1309–1312 (1998). DOI: 10.1126/science.281.5381.1309
15. Grenell, R. G., Mendelson, J., and McElroy, W. D., Effects of chlorpromazine on metabolism in central nervous system.AMA Arch. Neurol. Psychiat., 73, 347–351 (1955).
16. Guth, R. S. and Spirtes, M. A., The phenothiazine tranquilizers: biochemical and biophysical actions.Int. Rev. Neurobio. I7, 231–278 (1964). DOI: 10.1016/S0074-7742(08)60269-X
17. Jeste, D. V., Lacro, J. P., Bailey, A., Rockwell, E., Harris, M. J., and Caligiuri, M. P., Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.J. Am. Geriatr. Soc., 47(6), 716–719 (1999).
18. Lemmens, P., Breecher, M., and Van Baelen, B. A., Combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms.Acta Psychiatr. Scand., 99(3), 160–170 (1999). DOI: 10.1111/j.1600-0447.1999.tb00972.x
19. Loft, S., Astrup, A., Buemann, B., and Poulsen, H. E., Oxidative DNA damage correlated with oxygen consumption in humans.FASEB J., 8, 534–537 (1994).
20. Maurer, I. and Molle, H.-J., Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics.Mol. Cell Biochem., 174, 255–259 (1998). DOI: 10.1023/A:1006872911332
21. Mitchell, I. J., Crossman, A. R., Liminga, U., Andren, P., and Gunne, L. M., Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey.Mov. Disord., 7, 32–37 (1992). DOI: 10.1002/mds.870070106
22. Modica-Napolitano, J. S., Joyal, J. L., Ara, G., Oseroff, A. R., and Aprille, J. R., Mitochondrial toxicity of cationic photosensitizers for photochemotherapy.Cancer Res., 50, 7876–7881 (1990).
23. Prince, J. A., Yassin, M. S., and Oreland, L., Neuroleptic-induced mitochondrial enzyme alterations in rat brain.J. Pharmacol. Exptl. Therapeut., 280, 261–267 (1997).
24. Rand, D. M., Thermal habit, metabolic rate and the evolution of mitochondrial DNA.Trends Ecol. Evol., 9, 125–131 (1994). DOI: 10.1016/0169-5347(94)90176-7
25. Roberts, R. C., Gaither, L. A., Gao, X.-M., Kashyap, S. M., and Tammainga, C. A., Ultrastructural correlates of haloperidol-induced oral dyskinesis in rat striatum.Synapse, 20, 234–243 (1995). DOI: 10.1002/syn.890200307
26. Schapira, A. H. V., Evidence for mitochondrial dysfunction in Parkinsons Disease-a critical appraisal.Mov. Disord., 9, 125–138 (1998). DOI: 10.1002/mds.870090202
27. Schillevoort, I., de Boer, A., Herings, R. M., Roos, R. A., Jansen, P. A., and Leufkens, H. G., Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.Ann. Pharmacother., 35, 1517–22 (2001). DOI: 10.1345/aph.1A068
28. Sussman, N., Choosing an atypical antipsychotic.Int. Clin. Psychopharmacol., 17(3), 29–33 (2002).
29. Tarsy, D. and Baldessarini, R. J., Tardive Dyskinesia.Ann. Rev. Med., 35, 605–623 (1984). DOI: 10.1146/annurev.me.35.020184.003133
30. Tarsy, D., Baldessarini, R. J., and Tarazi, F. I., Effects of newer antipsychotics on extrapyramidal function.CNS Drugs, 16, 23–45 (2002). DOI: 10.2165/00023210-200216010-00003